quinazolines has been researched along with bl 4162a in 292 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (6.51) | 18.7374 |
| 1990's | 36 (12.33) | 18.2507 |
| 2000's | 127 (43.49) | 29.6817 |
| 2010's | 89 (30.48) | 24.3611 |
| 2020's | 21 (7.19) | 2.80 |
| Authors | Studies |
|---|---|
| Buyniski, JP; Fleming, JS | 1 |
| Mazur, EM; Narendran, A; Newton, JL; Rosmarin, AG; Sohl, PA | 1 |
| Balduini, CL; Ferrari, A; Mazzucconi, MG | 1 |
| Hoagland, HC; McIntyre, KJ; Petitt, RM; Silverstein, MN | 1 |
| Frenkel, EP | 1 |
| Chintagumpala, MM; Fernbach, DJ; Mahoney, DH; Ogden, AK; Steuber, CP | 1 |
| Gillespie, E | 1 |
| Arnold, AJ; Fifer, CA; Grove, RI; Keely, SL; Seiler, S; Stanton, HC | 1 |
| Alvarez, R; Bruno, JJ; Stephenson, RA; Strosberg, AM; Venuti, MC | 1 |
| Alvarez, R; Kenley, RA; Lin, LH; Venuti, MC; Visor, GC | 1 |
| de Clerck, F; van de Wiele, R; Xhonneux, B | 1 |
| Alvarez, R; Berks, AH; Bruno, JJ; Jones, GH; Prince, A; Venuti, MC | 1 |
| Baryla, UM; Fleming, JS; Stanton, HC | 1 |
| Fleming, JS; Knight, RC; Petitt, RM; Schacter, LP; Silverstein, MN; Solberg, LA | 1 |
| Adamson, JW | 1 |
| Ambrus, CM; Ambrus, JL; Gastpar, H | 1 |
| Gallo, DG; Kerns, EH; Russell, JW | 1 |
| Benedict, CR; Cartwright, J; Mathew, B; Rex, KA; Sordahl, LA | 1 |
| Duchastel, A; Frojmovic, MM; Milton, JG | 1 |
| Abe Andes, W; Fleming, JS; Noveck, RJ | 1 |
| Barrett, PA; Butler, KD | 1 |
| Smith, JB | 1 |
| Clark, WF; Moriarity, TA; Reid, BD; Tevaarwerk, GJ | 1 |
| Deeb, G; Gaver, RC; Pittman, KA; Smyth, RD | 1 |
| Brogden, RN; Spencer, CM | 1 |
| Mughal, TI | 1 |
| Chintagumpala, MM; Kennedy, LL; Steuber, CP | 1 |
| Hołub, A; Robak, T; Treliński, J | 1 |
| Hasselbalch, HC; Jensen, BA; Mourits-Andersen, HT; Nielsen, OJ | 1 |
| Griesshammer, M; Hehlmann, R; Lengfelder, E | 1 |
| Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ | 1 |
| Petitt, RM; Petrone, ME; Silverstein, MN | 1 |
| Elliott, MA; Silverstein, MN; Solberg, LA; Tefferi, A | 1 |
| Mesa, RA; Petitt, RM; Silverstein, MN; Solberg, LA; Tefferi, A | 1 |
| Forstrom, LA; Oles, KJ; Petitt, RM; Silverstein, MN; Solberg, LA; Tarach, JS; Tefferi, A | 1 |
| Beykirch, MK; Petrides, PE; Trapp, OM | 2 |
| Lindemann, A; Mertelsmann, R; Schoepf, E; Wirth, K | 1 |
| Fuchs, D; Hempel, L; Hermann, J; Sauerbrey, A; Zintl, F | 1 |
| Sréter, L | 1 |
| Oertel, MD | 1 |
| Chernoff, SG; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Ruiz-Reyes, G | 1 |
| Adam, H; Burkhard, R; Honegger, HP; Widmer, L | 1 |
| Silverstein, MN; Tefferi, A | 2 |
| Bennett, CL; Golub, RM; Weinberg, PO | 1 |
| Bellucci, S; Boval, B; Caen, J; Drouet, L; Legrand, C | 1 |
| Bashford, J; Brigden, MC; Bunce, I; Eliadis, P; Kelly, C; Mills, AK; Olsen, T; Rentoul, A; Seeley, G; Taylor, KM; Wright, SJ | 1 |
| Li, CY; Mesa, RA; Tefferi, A; Yoon, SY | 1 |
| Alemany, M; Bellucci, S; Caen, JP; Han, ZC | 1 |
| Brooks, WG; Goode, JV; Stanley, DD | 1 |
| Barbui, T; Finazzi, G; Fuchtman, SM; Kutti, J; Michiels, JJ; Rain, JD; Silver, RT; Tefferi, A; Thiele, J | 1 |
| Kornblihtt, LI; Laguna, MS; Marta, RF; Michiels, JJ; Molinas, FC | 1 |
| Green, AR | 1 |
| Bennett, M | 1 |
| James, CW | 1 |
| Balon, J; Bieniaszewska, M; Hellmann, A | 1 |
| Hehlmann, R; Lengfelder, E | 1 |
| Storen, EC; Tefferi, A | 1 |
| Kornblihtt, LI; Laguna, MS; Marta, RF; Molinas, FC | 1 |
| Lindley, C; Pescatore, SL | 1 |
| Pavithran, K; Somarajan, A; Thomas, M | 1 |
| Cervantes, F | 2 |
| Briere, J; Guilmin, F | 1 |
| Bangerter, M; Griesshammer, M; Grünewald, M | 1 |
| Tefferi, A; Wright, CA | 1 |
| Bennett, M; Grunwald, AJ | 1 |
| Hysing, J; Knutsen, H | 1 |
| Ikeda, Y | 1 |
| Gilbert, HS | 3 |
| Blanset, DL; Dias, S; Hattori, K; Lane, WJ; Lang, PC; Moore, MA; Peerschke, EI; Petrone, M; Rafii, S | 1 |
| Eftyhiadis, E; Komninaka, V; Loukopoulos, D; Mantzourani, M; Terpos, E; Voskaridou, E | 1 |
| Tomer, A | 1 |
| Solberg, LA | 1 |
| Adams, J; Bennett, CL; Dave, S; Golub, R | 1 |
| Lev, PR; Marta, RF; Molinas, FC; Vassallu, P | 1 |
| Erusalimsky, JD; Franklin, R; Hong, Y | 1 |
| Heller, P; Kornblihtt, LI; Molinas, FC; Vassallu, PS | 1 |
| Andersson, BS | 1 |
| Kvasnicka, HM; Schmitt-Gräff, A; Thiele, J | 1 |
| Giles, FJ; Tsimberidou, AM | 1 |
| Erusalimsky, JD; Hong, Y | 1 |
| Brink, JS; Brown, AK; Moir, C; Palmer, BA; Rodeberg, DR | 1 |
| Barbui, T | 2 |
| Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M | 1 |
| Albitar, M; Colburn, DE; Cortes, JE; Giles, FJ; Kantarjian, HM; O'Brien, SM; Tsimberidou, AM; Verstovsek, S; Welch, MA | 1 |
| Brink, DJ; Mazer, MA; Raghavan, M | 1 |
| Griesshammer, M; Langer, C | 1 |
| Brunnbauer, K; Fuchs, N; Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J; Volkwein, N | 1 |
| Castañón, M; Correa, G; Genoud, V; Heller, PG; Kordich, L; Kornblihtt, LI; Molinas, FC; Sarano, J; Vassallu, P | 1 |
| Schafer, AI | 1 |
| Birgegård, G; Björkholm, M; Kutti, J; Lärfars, G; Löfvenberg, E; Markevärn, B; Mauritzson, N; Merup, M; Palmblad, J; Samuelsson, J; Westin, J | 2 |
| Putti, MC; Randi, ML | 1 |
| Cheung, MC; Hicks, LK; Pendergrast, J | 1 |
| Campbell, PJ; Curtin, N; Green, AR; Vassiliou, GS | 1 |
| Fruchtman, SM | 1 |
| Petrides, PE | 3 |
| Dingli, D; Tefferi, A | 2 |
| Brychtova, Y; Doubek, M; Doubek, R; Janku, P; Mayer, J | 1 |
| Fay, M; Murphy, PT; O'Donnell, R; Swords, R | 1 |
| Cacciola, E; Cacciola, RR; Francesco, ED; Giustolisi, R | 1 |
| Gastl, G; Gisslinger, H; Jedrzejczak, WW; Lin, W; Pytlik, R; Schlögl, E; Steurer, M | 1 |
| Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Mourits-Andersen, T; Nielsen, OJ; Penninga, E | 1 |
| Silver, RT | 1 |
| Bernasconi, S; Bizzoni, L; Dragoni, F; Latagliata, R; Mandelli, F; Mazzucconi, MG; Redi, R; Santoro, C | 1 |
| Jurgens, DJ; Moreno-Aspitia, A; Tefferi, A | 1 |
| Heller, PG; Kornblihtt, LI; Lev, PR; Marta, RF; Molinas, FC; Pirola, CJ; Salim, JP | 1 |
| Lafayette, RA; Rodwell, GE; Troxell, ML | 1 |
| Fiddler, G; Fruchtman, SM; Gilbert, HS; Lyne, A; Petitt, RM | 1 |
| Dame, C; Sutor, AH | 1 |
| Alkindi, S; Dennison, D; Pathare, A | 1 |
| Kuliczkowski, K; Kuliszkiewicz-Janus, M; Mazur, G; Nosol, J; Podolak-Dawidziak, M; Potoczek, S; Wróbel, T | 1 |
| Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE | 1 |
| Barbui, T; Finazzi, G | 2 |
| Gonthier, R; Neirinck, L; Zhu, Z | 1 |
| Cocorullo, S; Heller, PG; Kornblihtt, LI; Lylyk, P; Miranda, C; Molinas, FC | 1 |
| Erusalimsky, JD; Franklin, R; Hong, Y; Wang, G | 1 |
| Baughman, RP; Engel, PJ; Johnson, H; Richards, AI | 1 |
| Costello, R; O'Callaghan, T; Sébahoun, G | 1 |
| Kvasnicka, HM; Ollig, S; Schmitt-Gräff, A; Thiele, J | 1 |
| Cacciola, E; Cacciola, RR; Cipolla, A; Di Francesco, E; Giustolisi, R | 1 |
| Silver, R | 1 |
| Fruchtman, S | 1 |
| Keating, GM; Wagstaff, AJ | 1 |
| Dessypris, EN; Kanamori, D; McCarty, JM; Melone, PD; Simanis, JP; Warshamana-Greene, GS | 1 |
| Lawrence, DS; Spencer, EM | 1 |
| Gutknecht, D; Pachipala, K | 1 |
| Harrison, CN | 2 |
| Del Arroyo, AG; Erusalimsky, JD; Hernandez, J; Hong, Y; Skene, C; Wang, G | 1 |
| Najda, J; Stella-Hołowiecka, B | 1 |
| Jantunen, E; Kuittinen, T; Nousiainen, T; Penttilä, K | 1 |
| Birgegard, G | 4 |
| Cabello, P; Cesar, JM; Ferro, T; Navarro, JL | 1 |
| Belada, D; Brychtová, Y; Bubeník, B; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Kissová, J; Lhot'anová, T; Micaníková, M; Penka, M; Pytlík, R; Schutzová, M; Schwarz, J; Seghetová, J; Siroký, O; Szotkowski, T; Voglová, J; Volková, Z; Vozobulová, V; Vránová, M | 1 |
| Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J | 1 |
| Giles, F; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S | 1 |
| Gisslinger, H | 1 |
| Lee, LH; Wong, GC | 1 |
| Benesch, M; Dornbusch, HJ; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C | 1 |
| Chang, H; Cheong, JW; Choi, D; Jang, Y; Ko, YG; Pyo, JY; Shim, CY | 1 |
| Beránek, M; Chrobák, L; Maisnar, V; Voglová, J | 1 |
| Liu, D; Seiter, K; Yalamanchili, K | 1 |
| Goette, NP; Marta, RF; Molinas, FC | 1 |
| Bernhardt, B; Peerschke, EI; Silver, RT; Varon, D; Weksler, BB; Yin, W | 1 |
| Dissemond, J; Grabbe, S; Körber, A; Rappoport, L | 1 |
| Chao, TY; Lin, GM; Wang, WB | 1 |
| Birgegård, G; Engström-Laurent, A; Hultdin, M; Lundström, B; Samuelsson, J; Sundström, G; Wahlin, A | 1 |
| Brychtová, Y; Bubeník, B; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Kissová, J; Lhotanová, T; Micaníková, M; Pavlík, T; Penka, M; Pospísilová, D; Pytlík, R; Schützová, M; Schwarz, J; Seghetová, J; Szotkowski, T; Voglová, J; Volková, Z; Vozobulová, V; Vránová, M; Zapletal, O | 1 |
| Bennett, M; Chubar, E | 1 |
| Griesshammer, M | 2 |
| Reilly, JT | 2 |
| Bareford, D; Buck, G; Campbell, PJ; East, CL; Erber, WN; Green, AR; Harrison, CN; Paul, B; Wheatley, K; Wilkins, BS | 1 |
| Cacciola, E; Cacciola, RR; Di Francesco, E; Giustolisi, R; Pezzella, F; Tibullo, D | 1 |
| Cheng, G; Lam, LW; Wong, RS | 1 |
| D'adda, M; Drera, M; Ferrari, S; Micheletti, M; Rossi, G | 1 |
| Emadi, A; Spivak, JL | 1 |
| Anastasiadis, A; Bourikas, G; Christoforidou, A; Goutzouvelidis, A; Kaloutsi, V; Kotsianidis, I; Margaritis, D; Pantelidou, D; Spanoudakis, E; Tsatalas, C | 1 |
| de Stricker, K; Hasselbalch, HC; Larsen, TS; Møller, MB; Pallisgaard, N | 1 |
| Gisslinger, H; Krumpl, G; Linkesch, W; Petrides, PE; Schüller, A; Steurer, M; Widmann, R | 1 |
| Bareford, D; Buck, G; Campbell, PJ; Erber, WN; Green, AR; Harrison, CN; Wheatley, K; Wilkins, BS; Wright, P | 1 |
| Ardizzone, F; Maccio, S; Proietti, R; Rognoni, A; Rognoni, G; Santagostino, A | 1 |
| Besses, C; Burgaleta, C; Carbonell, F; Giralt, M; Hernández-Nieto, L; Navas, V; Ramírez, G; Vicente, V | 1 |
| Bello López, JL; Pérez Encinas, MM; Quinteiro García, C; Rabuñal Martinez, MJ; Sobas, MA | 1 |
| Beer, PA; Green, AR | 1 |
| Bodzásová, C; Brychtová, Y; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Indrák, K; Jelínková, P; Jonásová, A; Kissová, J; Korístek, Z; Nováková, L; Pavlík, T; Penka, M; Pospísilová, D; Schutzová, M; Schwarz, J; Segethová, J; Voglová, J; Vozobulová, V; Walterová, L | 1 |
| Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB | 1 |
| Schlag, R; Schmitz, S; Stauch, M | 1 |
| Vannucchi, AM | 1 |
| Ahluwalia, M; Butcher, L; Donovan, H; Erusalimsky, JD; Singh, N | 1 |
| Buliková, A; Doubek, M; Dulícek, P; Hlusí, A; Kissová, J; Korístek, Z; Ovesná, P; Pavlík, T; Penka, M; Pospísilová, D; Schwarz, J | 1 |
| Cacciola, E; Cacciola, R; Candoni, A; Ciancia, R; Codeluppi, K; Crugnola, M; Grossi, A; Gugliotta, L; Iurlo, A; Liberati, AM; Lunghi, M; Martinelli, V; Mazzucconi, MG; Palmieri, F; Pierri, I; Scalzulli, PR; Specchia, G; Tieghi, A; Tortorella, G; Usala, E; Vannucchi, AM; Vianelli, N | 1 |
| Besses, C; Martínez-Sellés, M | 1 |
| How, CK; Huang, MS; Su, PH; Yen, DH | 1 |
| Finazzi, G | 1 |
| Dubiel, JS; Dudek, D; Dziewierz, A; Kleczyński, P; Olszanecka, A; Rakowski, T; Wiliński, J | 1 |
| Cebula-Obrzut, B; Chojnowski, K; Smolewski, P; Treliński, J | 1 |
| Chen, YG; Chian, CF; Lin, CS; Shen, CH | 1 |
| Dowson, A; Frewin, R | 1 |
| Alvarez-Larrán, A; Besses, C; Coll, R; Freitag, C; Martin, P; Purkayastha, J; Troy, S; Zeller, W | 1 |
| Andreasson, B; Birgegård, G; Björkholm, M; Ejerblad, E; Kvasnicka, HM; Löfvenberg, E; Markevärn, B; Merup, M; Nilssson, L; Palmblad, J; Samuelsson, J; Thiele, J | 1 |
| García-Sanchez, R; Plaza, S; Ramirez, G | 1 |
| Datino, T; Fernández-Avilés, F; Figueiras-Graillet, L; Franklin, R; Gama, JG; Jones, C; Martínez-Sellés, M | 1 |
| Besses, C; Birgegård, G; Coll, R; Griesshammer, M; Gugliotta, L; Harrison, C; Kiladjian, JJ; Smith, J | 1 |
| Abhyankar, B; Besses, C; Birgegård, G; Coll, R; Griesshammer, M; Gugliotta, L; Harrison, C; Kiladjian, JJ; Smith, J | 2 |
| Gisslinger, H; Gotic, M; Holowiecki, J; Kralovics, R; Kvasnicka, HM; Penka, M; Petrides, PE; Thiele, J | 1 |
| Alvarez-Larrán, A; Antelo, ML; Arellano-Rodrigo, E; Besses, C; Cervantes, F; Ferrer-Marín, F; Gómez, M; Hernández-Boluda, JC; Kerguelen, A; Márquez, JA; Pereira, A | 1 |
| Abhyankar, B; Hodgson, I; Kanakura, Y; Miyakawa, Y; Okamoto, S; Smith, J; Troy, S | 1 |
| Alvarez-Larrán, A; Besses, C; Cervantes, F | 1 |
| Haznedaroglu, IC | 1 |
| Cervinek, L; Dulíček, P; Kissová, J; Ovesná, P; Pavlík, T; Penka, M; Pospíšilová, D; Schwarz, J | 1 |
| Schaaf, M; Sibellas, F | 1 |
| Fu, R; Yang, R; Zhang, L | 1 |
| Keddad, K; Kiladjian, JJ; Rey, J; Smith, J; Viallard, JF; Wilde, P | 1 |
| Cortelazzo, S; Corvetta, D; Gastl, G; Mazzoleni, G; Piccin, A; Pusceddu, I; Rovigatti, U; Steurer, M; Svaldi, M | 1 |
| Ahn, IE; Natelson, E; Rice, L | 1 |
| Chaudhary, R; Nityanand, S; Singh, A | 1 |
| Newberry, KJ; Sever, M; Verstovsek, S | 1 |
| Balasubramaniam, K; Dragone, J; Grose-Hodge, R; Martin, P; Preston, P; Troy, S; Viswanathan, G; Zaman, AG | 1 |
| Ballester-Sánchez, R; de Unamuno-Bustos, B; Sabater Marco, V; Vilata-Corell, JJ | 1 |
| Kim, YS; Lee, SH | 1 |
| Fülöpová, V; Grepl, M; McMaster, C; Popa, I; Soural, M | 1 |
| De Raeve, H; Gadisseur, A; Michiels, JJ; Pich, A | 1 |
| Achenbach, H; Kanakura, Y; Miyakawa, Y; Okamoto, S; Smith, J; Wilde, P | 1 |
| Bourkova, L; Bulikova, A; Kissova, J; Ovesna, P; Penka, M | 1 |
| Miyamoto, T; Yoshimoto, G | 1 |
| Bergmann, F; Griesshammer, M; Koschmieder, S; Kreher, S; Matzdorff, A; Ochsenreither, S; Pabinger, I; Petrides, PE; Riess, H; Tiede, A; Trappe, RU | 1 |
| Espasandin, YR; Glembotsky, AC; Goette, NP; Grodzielski, M; Heller, PG; Lev, PR; Marta, RF; Molinas, FC | 1 |
| Double, G; Harrison, C | 1 |
| Bang, SM; Kim, JW; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW; Lim, Y | 1 |
| Brychtová, Y; Campr, V; Černá, O; Červinek, L; Cmunt, E; Doubek, M; Dulíček, P; Kissová, J; Křen, L; Maaloufová Soukupová, J; Ovesná, P; Penka, M; Schwarz, J | 1 |
| Birtolo, C; Codeluppi, K; Cortelazzo, S; Fama, A; Gastl, G; Gugliotta, G; Gugliotta, L; Marcheselli, L; Piccin, A; Santoro, U; Steurer, M; Tieghi, A; Tortorella, G | 1 |
| Ahluwalia, M; Butcher, L; Donovan, H; Erusalimsky, JD; Jones, PM; Killick-Cole, C | 1 |
| Hoffman, R; Kremyanskaya, M; Mascarenhas, J | 1 |
| Chai-Adisaksopha, C; Garcia, D; Samuelson, B | 1 |
| Achenbach, H; Cascavilla, N; D'Adda, M; De Stefano, V; Fjerza, R; Gaidano, G; Gobbi, M; Iurlo, A; Liberati, AM; Palandri, F; Pancrazzi, A; Pane, F; Smith, J; Specchia, G; Vannucchi, AM; Wilde, P | 1 |
| Alvarez, C; Ferrari, L; Glembotsky, AC; Goette, NP; Gutierrez, MI; Heller, PG; Korin, L; Lev, PR; Maldonado, AC; Marta, RF; Mela Osorio, MJ; Molinas, FC | 1 |
| Cao, X; Fu, J; Gao, D; Ge, X; Hou, M; Jiang, B; Jin, J; Li, J; Li, K; Qian, W; Su, L; Sun, A; Wang, S; Wang, Z; Xiao, Z; Yang, L; Yang, R; Zhang, W; Zhang, X; Zhao, Y | 1 |
| Aksu, S; Büyükaşık, Y; Eliaçık, E; Göker, H; Haznedaroğlu, İC; Işık, A; Özcebe, OI; Sayınalp, N; Üner, A | 1 |
| Antelo, ML; de Las Heras, N; Gonzalez Porras, JR; Kerguelen, A; Raya, JM | 1 |
| Burlando, M; Cattaneo, D; Cozzani, E; Gugliotta, L; Iurlo, A; Merlo, G; Parodi, A; Pierri, I | 1 |
| Tersak, JM; Wigton, JC | 1 |
| Iványi, JL; Marton, É; Plander, M; Szendrei, T | 1 |
| Besses, C; Burgaleta, C; Hernández-Boluda, JC; Hernández-Rivas, JM; Jiménez Velasco, A; Martínez Lopez, J; Pérez Encinas, M; Raya, JM; Vicente, V | 1 |
| Buxhofer-Ausch, V; Gastl, G; Gisslinger, B; Gisslinger, H; Ruckser, R; Schimetta, W; Schloegl, E; Sormann, S; Steurer, M | 1 |
| Bucelli, C; Cattaneo, D; Cortelezzi, A; Fabris, S; Iurlo, A; Orofino, N | 1 |
| Fujiwara, T; Fukuhara, N; Harigae, H; Hasegawa, S; Ichinohasama, R; Okitsu, Y; Onishi, Y; Sakurai, K; Yamada-Fujiwara, M | 1 |
| Akay, OM; Andıç, N; Bolaman, AZ; Kadıköylü, VG; Ünübol, M; Yağcı, E; Yavaşoğlu, İ | 1 |
| Arnold, R; Bal, G; Bozzetti, C; Fransecky, L; Hemmati, P; le Coutre, P; Richter, U; Riess, H; Schulz, CO; Türkmen, S | 1 |
| Bertele', V; Garattini, S; Gerardi, C; Joppi, R | 1 |
| Kitanaka, A; Shimoda, K | 1 |
| Fujimura, K; Shimazu, Y | 1 |
| Demeter, J; Dombi, P; Egyed, M; Homor, L; Illés, Á; Karadi, E; Simon, Z; Udvardy, M | 1 |
| Uz, B | 1 |
| Demeter, J; Dombi, P; Egyed, M; Homor, L; Illés, Á; Karádi, É; Kellner, Á; Simon, Z; Udvardy, M | 1 |
| Corvetta, D; Di Pierro, AM; Eakins, E; Feistritzer, C; Gambato, R; Gastl, G; Gherlinzoni, F; Gottardi, M; Krampera, M; Langes, M; Marcheselli, L; Mazzoleni, G; Mega, A; Murphy, C; Pacquola, E; Perbellini, O; Piccin, A; Piva, E; Plebani, M; Pusceddu, I; Steurer, M; Tauber, M; Van Schilfgaarde, M; Veneri, D | 1 |
| Jilma, B; Klade, CS; Petrides, PE; Schoergenhofer, C; Widmann, R | 1 |
| Ito, T; Kajiguchi, T; Kamoshita, S; Kimura, T; Yagi, M | 1 |
| Baek, S; Choi, SY; Lee, H; Na, J | 1 |
| Alimena, G; Anaclerico, B; Andriani, A; Avvisati, G; Baldacci, E; Breccia, M; Buccisano, F; Cedrone, M; Cimino, G; De Gregoris, C; De Muro, M; Di Veroli, A; Latagliata, R; Leonetti Crescenzi, S; Mazzucconi, MG; Montanaro, M; Montefusco, E; Porrini, R; Rago, A; Santoro, C; Spadea, A; Sperduti, I; Spirito, F; Villivà, N | 1 |
| Kanai, A; Matsuda, K; Morokawa, H; Nakazawa, Y; Shimazaki, E | 1 |
| Berveiller, P; Cornet, N; Mir, O; Vialard, F | 1 |
| Usui, N | 1 |
| Greenspan, A; Lu, M; Rodriguez-Ziccardi, M; Rubio, M | 1 |
| Hwang, JH; Kim, DW; Kim, KS; Lee, SY | 1 |
| Atkinson, E; Bakri, M; Hayat, A; Langabeer, SE | 1 |
| Abd-Elmonem, MS; Abdel Maksoud, MIA; Abdel-Khalek, EK; Abdeltwab, E; Ashour, AH; El-Batal, AI; El-Okr, MM; El-Sayyad, GS; Hendawy, HAM; Labib, S | 1 |
| Begna, KH; Christopher Hook, C; Elliott, MA; Gangat, N; Hanson, CA; Ketterling, RP; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vallapureddy, RR; Wolanskyj, AP | 1 |
| Achenbach, H; Besses, C; Birgegård, G; Folkvaljon, F; Garmo, H; Griesshammer, M; Gugliotta, L; Harrison, CN; Holmberg, L; Kiladjian, JJ; Wu, J | 1 |
| Dalby, A; Watson, SP | 1 |
| Cervera, A; Gebreyohannes, YK; Hautaniemi, S; Icay, K; Joensuu, H; Kallioniemi, O; Keskitalo, S; Kulesskiy, E; Laakkonen, P; Laaksonen, M; Lehtonen, R; Mpindi, JP; Murumägi, A; Pulkka, OP; Schöffski, P; Sihto, H; Tynninen, O; Varjosalo, M; Wennerberg, K; Wozniak, A | 1 |
| Kuznetsova, PI; Melikyan, AL; Raskurazhev, AA; Subortseva, IN; Tanashyan, MM | 1 |
| Fujita, S; Hashimoto, A; Hashimoto, Y; Hotta, M; Ishii, K; Ito, T; Kondo, T; Konishi, A; Nakanishi, T; Nakaya, A; Nomura, S; Omura, H; Satake, A; Shinzato, I; Tanaka, T; Tanaka, Y; Yoshimura, H | 2 |
| Fukuda, Y; Hamano, Y; Iizuka, H; Inano, T; Izumi, H; Nakamura, N; Noguchi, M; Okubo, M; Sakajiri, S; Sawada, T; Sekiguchi, Y; Sugimoto, K; Takizawa, H; Tomita, S; Wakabayashi, M | 1 |
| Eto, K; Hino, Y; Iseki, T; Isshiki, Y; Iwama, A; Kayamori, K; Kimura, K; Mimura, N; Mitsukawa, S; Nakamura, S; Nakaseko, C; Ohwada, C; Oshima, M; Oshima-Hasegawa, N; Sakaida, E; Takaishi, K; Takayama, N; Takeda, Y; Takeuchi, M; Tsukamoto, S; Yokote, K | 1 |
| Besses, C; Blau, IW; Dong, T; Durrant, S; Francillard, N; Griesshammer, M; Harrison, CN; Hino, M; Kiladjian, JJ; Kirito, K; Masszi, T; Mesa, R; Miller, CB; Moiraghi, B; Pane, F; Passamonti, F; Rosti, V; Rumi, E; Vannucchi, AM; Verstovsek, S; Wroclawska, M; Zachee, P | 1 |
| Arimura, A; Fujii, K; Hashiguchi, T; Hayashida, M; Higashi, Y; Kanekura, T | 1 |
| Anaclerico, B; Andriani, A; Baldacci, E; Breccia, M; Cedrone, M; Cimino, G; Di Veroli, A; Latagliata, R; Mazzucconi, MG; Montanaro, M; Montefusco, E; Paoloni, F; Porrini, R; Rago, A; Santoro, C; Scaramucci, L; Spadea, A; Spirito, F; Villivà, N | 1 |
| Demeter, J; Dombi, P; Egyed, M; Ercsei, I; Gasztonyi, Z; Gy Korom, V; Herczeg, J; Homor, L; Illes, A; Karadi, E; Kellner, A; Simon, Z; Szerafin, L; Udvardy, M | 1 |
| Alvarez-Larrán, A; Andrade-Campos, M; Angona, A; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Ferrer-Marín, F; Fox, L; García-Gutiérrez, V; García-Hernández, C; Guerrero, L; Hernández-Boluda, JC; Isabel Mata-Vázquez, M; Magro, E; Manuel Alonso-Domínguez, J; María Guerra, J; María Raya, J; Moretó, A; Murillo, I; Palomino, A; Pastor-Galán, I; Pérez-Encinas, M; Soledad Noya, M; Teresa Gómez-Casares, M | 1 |
| Achenbach, H; Egyed, M; Gercheva, L; Gotic, M; Kvasnicka, HM; Warzocha, K; Wu, J | 1 |
| Fukushima, K; Gatate, Y; Muramatsu, T; Naganuma, K; Nakano, S; Ohta, A; Shimizu, Y; Sujino, Y; Tanaka, R; Todo, M; Watanabe, A | 1 |
| Jaźwiec, B; Kuliszkiewicz-Janus, M; Kwiatkowski, J; Małecki, R; Rymer, W | 1 |
| Cario, H; Duffert, CM; Knöfler, R; Kulozik, AE; Stockklausner, C; Streif, W | 1 |
| Krečak, I; Lucijanić, M | 1 |
| Oskay, T; Özen, M | 1 |
| Chen, J; Gao, S; Huang, N; Huang, Y; Li, D; Liu, N; Qi, X; Sun, Y; Wang, HW; Wang, X; Wang, Y; Wu, Q | 1 |
| Ebata, K; Nakamura, H; Narahira, A; Nohara, T; Sugai, T; Ujiie, H; Yamaguchi, Y | 1 |
| Akimoto, T; Baba, T; Fernandez, J; Hashimoto, Y; Komatsu, N; Otsuka, M | 1 |
| Fleischman, A; Gotlib, J; Heaney, M; Hoffman, R; Kremyanskaya, M; Kuykendall, A; Mascarenhas, J; Mesa, R; O'Connell, C; Podoltsev, N; Rippel, N; Shammo, JM; Tremblay, D; Yacoub, A; Zubizarreta, N | 1 |
| Gill, H; Hou, HA; Jin, J; Komatsu, N; Lee, SE; Mesa, RA; Qin, A; Sato, T; Shih, W; Urbanski, R; Verstovsek, S; Zagrijtschuk, O; Zimmerman, C | 1 |
| Alvarez-Larrán, A; Ferrer-Marín, F; Santaliestra, M | 1 |
| Bieniaszewska, M; Dutka, M; Leszczyńska, A; Sobieralski, P | 1 |
| Dai, Y; Ehnstrom, J; Li, H; Milton, M; Santos, W; Zell, M | 1 |
76 review(s) available for quinazolines and bl 4162a
| Article | Year |
|---|---|
[Essential thrombocythemia: therapy with anagrelide].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Drug Evaluation; Female; Hematopoiesis; Humans; Male; Megakaryocytes; Phospholipases A; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential | 1991 |
The clinical spectrum of thrombocytosis and thrombocythemia.
Topics: Blood Platelets; Cytokines; Hematopoiesis; Humans; Hydroxyurea; Interferon Type I; Megakaryocytes; Platelet Aggregation; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 1991 |
Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Child; Clinical Trials as Topic; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 1994 |
Primary thrombocythemia: a current perspective.
Topics: Aspirin; Diagnosis, Differential; Humans; Hydroxyurea; Interferon Type I; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Plateletpheresis; Quinazolines; Recombinant Proteins; Thrombocytosis | 1995 |
Treatment of essential thrombocythemia with anagrelide.
Topics: Adolescent; Blood Cell Count; Bone Marrow Examination; Child; Drug Evaluation; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 1995 |
[Anagrelide--new antiplatelet drug].
Topics: Animals; Chronic Disease; Humans; Megakaryocytes; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines | 1994 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; Busulfan; Female; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Incidence; Interferon-alpha; Ischemic Attack, Transient; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis | 1996 |
Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.
Topics: Fibrinolytic Agents; Humans; Polycythemia; Quinazolines; Thrombocytosis | 1997 |
New drugs in essential thrombocythemia and polycythemia vera.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Interferon alpha-2; Interferon-alpha; Polycythemia Vera; Quinazolines; Recombinant Proteins; Thrombocytosis | 1997 |
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Topics: Animals; Bone Marrow; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Hematopoiesis; Hemodynamics; Humans; Megakaryocytes; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombosis | 1997 |
Anagrelide, a selective thrombocytopenic agent.
Topics: Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 1998 |
Treatment of essential thrombocythemia with anagrelide.
Topics: Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 1999 |
Regulation of megakaryocytopoiesis.
Topics: Animals; Chemokines; Clinical Trials as Topic; Cytokines; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Interferon-alpha; Macaca mulatta; Megakaryocytes; Neoplasm Proteins; Neoplasms; Platelet Factor 4; Proto-Oncogene Proteins; Quinazolines; Radiation Injuries, Experimental; Receptors, Cytokine; Receptors, Thrombopoietin; Recombinant Proteins; Thrombin; Thrombocytopenia; Thrombopoietin; Transforming Growth Factor beta | 1999 |
Role of anagrelide in the treatment of thrombocytosis.
Topics: Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 1999 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Thrombosis | 1998 |
Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
Topics: Blood Platelets; Forecasting; Humans; Hydroxyurea; Interferon-alpha; Megakaryocytes; Platelet Aggregation Inhibitors; Polycythemia Vera; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic | 2000 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia | 1999 |
[Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
Topics: Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 1999 |
[Polycythemia vera: current status of therapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Middle Aged; Phlebotomy; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Thromboembolism | 2000 |
Anagrelide: a novel agent for the treatment of myeloproliferative disorders.
Topics: Clinical Trials as Topic; Drug Approval; Fibrinolytic Agents; Humans; Myeloproliferative Disorders; Quinazolines; United States; United States Food and Drug Administration | 2000 |
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
Topics: Aged; Anemia; Aneuploidy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Case Management; Combined Modality Therapy; Female; Hemoglobins; Humans; Hydroxyurea; Karyotyping; Male; Middle Aged; Palliative Care; Primary Myelofibrosis; Prognosis; Quinazolines; Risk; Severity of Illness Index; Splenectomy; Survival Analysis; Thalidomide | 2001 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Progression; Female; Hemorrhagic Disorders; Humans; Hydroxyurea; Interferons; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Quinazolines; Risk; Safety; Thrombocythemia, Essential; Thrombophilia | 2001 |
Current treatment practice for essential thrombocythaemia in adults.
Topics: Adult; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Prognosis; Quinazolines; Thrombocythemia, Essential | 2001 |
A single institutional experience with 43 pregnancies in essential thrombocythemia.
Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulfan; Erythromelalgia; Female; Fetal Death; Follow-Up Studies; Heparin; Humans; Hydroxyurea; Migraine Disorders; Obstetric Labor, Premature; Phosphorus Radioisotopes; Platelet Aggregation Inhibitors; Platelet Count; Plateletpheresis; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy, Ectopic; Pregnancy, High-Risk; Quinazolines; Retrospective Studies; Risk; Thrombocythemia, Essential; Uterine Hemorrhage | 2001 |
Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
Topics: Enzyme Inhibitors; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Polycythemia Vera; Quinazolines; Thrombocytosis | 2001 |
Therapeutic options for essential thrombocythemia and polycythemia vera.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Busulfan; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Phosphorus Radioisotopes; Polycythemia Vera; Quinazolines; Risk Assessment; Thrombocytosis | 2002 |
Other secondary sequelae of treatments for myeloproliferative disorders.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Polycythemia; Quinazolines; Thrombocytosis | 2002 |
Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
Topics: Antineoplastic Agents; Blood Platelets; Contraindications; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2002 |
Essential thrombocythemia (ET): moving from palliation to cure.
Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Male; Palliative Care; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Recombinant Proteins; Thrombocythemia, Essential | 2002 |
Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review.
Topics: Blood Platelets; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Risk Assessment; Thrombocytosis | 2002 |
Portal vein thrombosis after laparoscopy-assisted splenectomy and cholecystectomy.
Topics: Anemia, Hemolytic, Autoimmune; Anticoagulants; Child; Cholecystectomy, Laparoscopic; Cholelithiasis; Drug Therapy, Combination; Female; Humans; Hypersplenism; Laparoscopy; Portal Vein; Postoperative Complications; Quinazolines; Splenectomy; Splenic Vein; Venous Thrombosis; Warfarin | 2003 |
Indications for lowering platelet numbers in essential thrombocythemia.
Topics: Age Factors; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis | 2003 |
Modern treatment strategies in polycythemia vera.
Topics: Age Factors; Antineoplastic Agents; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Phlebotomy; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Risk Factors | 2003 |
Pharmacotherapy of essential thrombocythaemia: economic considerations.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Quinazolines; Risk Factors; Thrombocythemia, Essential | 2003 |
Thrombocytosis.
Topics: Aspirin; Clone Cells; Diagnosis, Differential; Humans; Hydroxyurea; Interferon-alpha; Plasmapheresis; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 2004 |
Management of the myeloproliferative disorders : distinguishing data from dogma.
Topics: Abnormalities, Drug-Induced; Adult; Aged; Anticoagulants; Contraindications; Female; Humans; Hydroxyurea; Interferon-alpha; Male; Middle Aged; Myeloproliferative Disorders; Phlebotomy; Polycythemia Vera; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombophilia | 2004 |
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis | 2004 |
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals | 2004 |
Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
Topics: Animals; Carcinogens; Clinical Trials as Topic; Drug Therapy, Combination; Heart Diseases; Humans; Hydroxyurea; Interferon Type I; Mutagens; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Recombinant Proteins; Thrombocythemia, Essential; Thromboembolism | 2004 |
Anagrelide: an update on its mechanisms of action and therapeutic potential.
Topics: Clinical Trials as Topic; Drug Costs; Fibrinolytic Agents; Humans; Quinazolines; Thrombocytosis | 2004 |
Primary and secondary thrombocytosis in childhood.
Topics: Adolescent; Bacterial Infections; Blood Platelets; Child; Child, Preschool; Humans; Hydroxyurea; Infant; Infant, Newborn; Liver; Megakaryocytes; Mutation; Nucleic Acid Synthesis Inhibitors; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis; Thrombopoiesis; Thrombopoietin; Virus Diseases | 2005 |
A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Topics: Clinical Trials as Topic; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 2005 |
[Treatment of essential thrombocythemia].
Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Platelet Aggregation Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Thrombocythemia, Essential | 2005 |
Anagrelide: a review of its use in the management of essential thrombocythaemia.
Topics: Blood Platelets; Drug Tolerance; Hematologic Agents; Humans; Platelet Count; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential | 2006 |
Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
Topics: Animals; Fibrinolytic Agents; Humans; Myeloproliferative Disorders; Quinazolines; Thrombocytosis | 2005 |
[Clinical application of anagrelide as a selective inhibitor of megakaryocyte system].
Topics: Fibrinolytic Agents; Humans; Quinazolines; Thrombocytosis; Thrombopoiesis | 2005 |
Anagrelide treatment in myeloproliferative disorders.
Topics: Blood Platelets; Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines | 2006 |
Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial.
Topics: Disease Management; Humans; Hydroxyurea; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Treatment Outcome | 2006 |
Anagrelide: what was new in 2004 and 2005?
Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; History, 21st Century; Humans; Hydroxyurea; Male; Megakaryocytes; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Thrombocythemia, Essential | 2006 |
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Myeloproliferative Disorders; Philadelphia Chromosome; Quinazolines | 2006 |
Update on diagnosis and management of essential thrombocythemia.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Life Expectancy; Male; Quinazolines; Risk Factors; Thrombocythemia, Essential | 2006 |
[Primary thrombocythemia: diagnosis and therapy].
Topics: Adult; Aged; Aspirin; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Male; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Primary Prevention; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thrombocythemia, Essential; Time Factors | 2006 |
Myelofibrosis: biology and treatment options.
Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide | 2007 |
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Polycythemia Vera; Quinazolines; Risk Factors; Survival Analysis; Thrombocythemia, Essential | 2008 |
Long-term management of thrombocytosis in essential thrombocythaemia.
Topics: Algorithms; Antineoplastic Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pregnancy; PubMed; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombocytosis | 2009 |
Anagrelide: 20 years later.
Topics: Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 2009 |
Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review.
Topics: Adult; Amino Acid Substitution; Female; Fibrinolytic Agents; Humans; Infant, Newborn; Janus Kinase 2; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Quinazolines; Thrombocythemia, Essential | 2009 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid; Middle Aged; Models, Biological; Mutation, Missense; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombophilia | 2009 |
JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
Topics: Amino Acid Substitution; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Incidence; Interferon-alpha; Janus Kinase 2; Multicenter Studies as Topic; Mutation, Missense; Myeloproliferative Disorders; Phenotype; Point Mutation; Quinazolines; Thrombophilia; Thrombosis | 2010 |
Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
Topics: Blood Platelets; Humans; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential | 2009 |
How to manage essential thrombocythemia.
Topics: Female; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Interferon-alpha; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Risk Factors; Thrombocythemia, Essential | 2012 |
Headache in essential thrombocythaemia.
Topics: Alkylating Agents; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Headache Disorders; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Phosphorus Radioisotopes; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals; Risk Factors; Thrombocythemia, Essential | 2012 |
[Management of patients with essential thrombocythemia].
Topics: Adult; Aged; Bone Marrow; Cytostatic Agents; Disease Management; Female; Genetic Predisposition to Disease; Hemorrhage; Humans; Interferon-alpha; Janus Kinase 2; Lactation; Male; Middle Aged; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Thrombophilia | 2013 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progression; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Intraoperative Complications; Janus Kinase 2; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Mutation, Missense; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombophilia | 2013 |
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; GPI-Linked Proteins; Hemorrhage; Humans; Hydroxyurea; Incidence; Infant; Isoantigens; Janus Kinase 2; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Point Mutation; Primary Myelofibrosis; Quinazolines; Receptors, Cell Surface; Risk Assessment; Symptom Assessment; Thrombocythemia, Essential; Thrombophilia | 2013 |
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2014 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Immunosuppressive Agents; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Thrombopoietin; Thalidomide; Thrombocythemia, Essential | 2014 |
Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Polyethylene Glycols; Pyrazoles; Pyrimidines; Quinazolines | 2015 |
Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Topics: Hemorrhage; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombosis | 2015 |
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Female; Fibrosis; Humans; Hydroxyurea; Janus Kinase 2; Leukapheresis; Middle Aged; Myeloproliferative Disorders; Nitriles; Phlebotomy; Point Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Splenectomy; Splenomegaly | 2015 |
Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
Topics: Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Male; Myeloproliferative Disorders; Quinazolines | 2015 |
Essential Thrombocythemia: The Dermatologic Point of View.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Quinazolines; Skin Diseases; Thrombocythemia, Essential | 2015 |
Letting post-marketing bridge the evidence gap: the case of orphan drugs.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Barrett Esophagus; Cladribine; Dihematoporphyrin Ether; Ductus Arteriosus, Patent; Hepatolenticular Degeneration; Humans; Ibuprofen; Leukemia, Hairy Cell; Mitotane; Orphan Drug Production; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Quinazolines; Thrombocythemia, Essential; Zinc Acetate | 2016 |
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Topics: Age Factors; Bone Marrow; Cardiovascular Diseases; Humans; Interferon-alpha; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Tachycardia; Thrombocythemia, Essential | 2016 |
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Topics: Adolescent; Adult; Age of Onset; Algorithms; Anticoagulants; Calreticulin; Child; Disease Management; Female; Germ-Line Mutation; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Male; Myelodysplastic-Myeloproliferative Diseases; Platelet Count; Quinazolines; Receptors, Thrombopoietin; Severity of Illness Index; Thrombocythemia, Essential; Thrombocytosis; Thrombophilia | 2021 |
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Topics: Clinical Trials, Phase III as Topic; Humans; Hydroxyurea; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential | 2022 |
38 trial(s) available for quinazolines and bl 4162a
| Article | Year |
|---|---|
[Essential thrombocythemia: therapy with anagrelide].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Drug Evaluation; Female; Hematopoiesis; Humans; Male; Megakaryocytes; Phospholipases A; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential | 1991 |
Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
Topics: Aged; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis; Treatment Outcome | 1992 |
Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
Topics: Aged; Female; Hematologic Tests; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines | 1998 |
Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Quinazolines; Thrombocythemia, Essential | 1999 |
Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia.
Topics: Adult; Aged; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis | 2000 |
Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide.
Topics: Adolescent; Adult; Aged; Bone Marrow; Female; Fibroblast Growth Factor 2; Fibrosis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet-Derived Growth Factor; Quinazolines; Reticulin; Thrombocytosis; Transforming Growth Factor beta | 2002 |
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Topics: Adult; Aged; Chronic Disease; Diarrhea; Dose-Response Relationship, Drug; Female; Headache; Heart Rate; Humans; Male; Middle Aged; Myeloproliferative Disorders; Nausea; Patient Compliance; Patient Dropouts; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thrombocytosis | 2004 |
Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Count; Quinazolines; Thrombocytosis; Treatment Outcome | 2004 |
Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
Topics: Adult; Aged; Anemia; Chronic Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocytosis; Thromboembolism; Treatment Outcome | 2004 |
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Topics: Adult; Drug Resistance; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Quinazolines; Thrombocytosis | 2005 |
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombosis | 2005 |
[The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
Topics: Administration, Oral; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Finland; Follow-Up Studies; Humans; Male; Myeloproliferative Disorders; Prospective Studies; Quinazolines; Risk Assessment; Thrombocytosis; Treatment Outcome | 2006 |
[Megakaryopoietic cytokine levels in patients with essential thrombocythemia and their relationship with clinical and biochemical features].
Topics: Enzyme-Linked Immunosorbent Assay; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Megakaryocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Stem Cell Factor; Thrombocythemia, Essential; Thrombocytosis; Thrombopoiesis; Thrombopoietin | 2006 |
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Fibrinolytic Agents; Humans; Hyaluronic Acid; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombocytosis | 2007 |
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematology; Humans; Hydroxyurea; Megakaryocytes; Observer Variation; Pathology, Clinical; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocytosis | 2008 |
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Hydroxyurea; Male; Middle Aged; Peptide Fragments; Peptide Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Factor 4; Prothrombin; Quinazolines; Thrombocythemia, Essential; Thrombosis | 2007 |
TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.
Topics: Adult; Aged; Humans; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Receptors, Interleukin-6; Thrombocytosis; Thrombopoietin; Treatment Outcome | 2008 |
Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Chromatography, High Pressure Liquid; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Randomized Controlled Trials as Topic; Solubility; Therapeutic Equivalency; Thrombocytosis; Young Adult | 2009 |
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombosis | 2009 |
[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 2009 |
Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemia.
Topics: Adolescent; Adult; Age Factors; Aged; Area Under Curve; Biotransformation; Europe; Female; Half-Life; Hematologic Agents; Humans; Hydroxylation; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombopoiesis; Treatment Outcome; Young Adult | 2012 |
Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up.
Topics: Adult; Aged; Cohort Studies; Drug Administration Schedule; Follow-Up Studies; Humans; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Quinazolines; World Health Organization | 2013 |
Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions.
Topics: Adolescent; Adult; Analysis of Variance; Area Under Curve; Arrhythmias, Cardiac; Biotransformation; Caffeine; Chi-Square Distribution; Cross-Over Studies; Cytochrome P-450 CYP1A2; Drug Interactions; Electrocardiography; Fasting; Female; Food-Drug Interactions; Half-Life; Headache; Heart Rate; Hematologic Agents; Humans; Hydroxylation; Intestinal Absorption; London; Male; Metabolic Clearance Rate; Postprandial Period; Quinazolines; Young Adult | 2013 |
Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Topics: Age Factors; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Drug Substitution; Europe; Female; Hematologic Agents; Humans; Hydroxyurea; Kaplan-Meier Estimate; Male; Platelet Count; Prospective Studies; Quinazolines; Risk Factors; Thrombocythemia, Essential; Time Factors; Treatment Outcome | 2013 |
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study.
Topics: Adult; Aged; Aged, 80 and over; Europe; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Thrombocythemia, Essential; Treatment Outcome; Young Adult | 2013 |
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Maximum Tolerated Dose; Middle Aged; Nucleic Acid Synthesis Inhibitors; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Quinazolines; Retrospective Studies; Single-Blind Method; Thrombocythemia, Essential; World Health Organization; Young Adult | 2013 |
Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia.
Topics: Adult; Aged; Asian People; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Time Factors | 2013 |
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Topics: Adult; Aged; Aged, 80 and over; Drug Substitution; Female; France; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Retreatment; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Young Adult | 2014 |
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Cell Count; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interferons; Male; Middle Aged; Quinazolines; Thrombocythemia, Essential; Treatment Outcome; Young Adult | 2014 |
Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study.
Topics: Adult; Aspirin; Blood Coagulation; Blood Platelets; Cross-Over Studies; Drug Therapy, Combination; Headache; Humans; Imidazoles; Male; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombelastography; Thrombocytopenia; Thrombosis | 2014 |
Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blood Platelets; Female; Fibrinolytic Agents; Humans; Japan; Male; Middle Aged; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential; Time Factors | 2014 |
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study.
Topics: Adult; Aged; Cardiovascular Diseases; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Monitoring, Physiologic; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Troponin I | 2015 |
[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
Topics: Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2015 |
Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Fasting; Female; Fibrinolytic Agents; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Young Adult | 2018 |
Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Quinazolines; Thrombocythemia, Essential | 2018 |
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Nitriles; Pipobroman; Polycythemia Vera; Polyethylene Glycols; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Survival Rate; Time Factors | 2020 |
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Calreticulin; Child; Female; Follow-Up Studies; Genotype; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Mutation, Missense; Quinazolines; Registries; Spain; Thrombocythemia, Essential | 2021 |
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Topics: Adolescent; Adult; Aged; Biopsy; Blood Platelets; Bone Marrow Examination; Echocardiography; Europe; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Count; Quinazolines; Stroke Volume; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult | 2021 |
179 other study(ies) available for quinazolines and bl 4162a
| Article | Year |
|---|---|
A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A).
Topics: Adenosine Diphosphate; Animals; Carotid Arteries; Collagen; Dogs; Electricity; Fibrinolytic Agents; Haplorhini; Hemorrhage; Humans; Imidazoles; Lasers; Macaca mulatta; Platelet Aggregation; Quinazolines; Rabbits; Rats; Thrombosis | 1979 |
Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.
Topics: Cell Aggregation; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Kinetics; Megakaryocytes; Platelet Aggregation Inhibitors; Ploidies; Quinazolines; Thrombocytopenia; Time Factors | 1992 |
Essential thrombocythemia in young adults.
Topics: Adolescent; Adult; Child; Epinephrine; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Thrombosis | 1991 |
Essential thrombocythemia in a child: management with anagrelide.
Topics: Aspirin; Child; Drug Therapy, Combination; Humans; Male; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential | 1991 |
Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Blood Platelets; Dose-Response Relationship, Drug; Humans; Milrinone; Platelet Aggregation Inhibitors; Pyridones; Quinazolines; Theophylline | 1988 |
Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes.
Topics: Blood Platelets; Calcium; Cyclic AMP; Fibrinolytic Agents; Humans; Phosphorylation; Platelet Aggregation; Protein Kinase C; Quinazolines; Thrombin | 1987 |
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Cardiotonic Agents; Dogs; Drug Evaluation; Heart Failure; Humans; Myocardium; Platelet Aggregation; Quinazolines; Structure-Activity Relationship | 1988 |
Electrochemical evaluation of the interaction between ascorbic acid and the cardiotonic drug RS-82856.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Ascorbic Acid; Cardiotonic Agents; Drug Interactions; Electrochemistry; Platelet Aggregation Inhibitors; Quinazolines; Quinolones; Solutions | 1987 |
Biochemical mechanisms in 5-hydroxytryptamine-induced human platelet aggregation.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Adenylyl Cyclases; Arachidonic Acid; Arachidonic Acids; Blood Platelets; Calcium; Creatine Kinase; Humans; Papaverine; Phosphocreatine; Platelet Aggregation; Prostaglandins E; Quinazolines; Serotonin | 1985 |
Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Humans; Indicators and Reagents; Magnetic Resonance Spectroscopy; Mass Spectrometry; Myocardium; Quinazolines; Quinolines; Quinolones; Rats; Spectrophotometry, Infrared; Structure-Activity Relationship | 1987 |
The anesthetized ferret, an in vivo model for evaluating inotropic activity: effects of milrinone and anagrelide.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Carnivora; Drug Evaluation, Preclinical; Electrocardiography; Ferrets; Heart Rate; Milrinone; Myocardial Contraction; Pyridones; Quinazolines; Species Specificity | 1988 |
Anagrelide: a new drug for treating thrombocytosis.
Topics: Adult; Aged; Female; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 1988 |
Wither the platelet?
Topics: Humans; Platelet Count; Quinazolines; Thrombocytosis | 1988 |
Effect of imidazoquinazolinones on tumor cells in the circulation.
Topics: Animals; Antineoplastic Agents; Fibrinolytic Agents; Male; Mice; Mice, Inbred ICR; Neoplastic Cells, Circulating; Platelet Aggregation; Quinazolines | 1986 |
Determination of anagrelide in plasma by capillary gas chromatography-mass spectrometry.
Topics: Fibrinolytic Agents; Gas Chromatography-Mass Spectrometry; Humans; Quinazolines | 1987 |
Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation.
Topics: Adenosine Diphosphate; Animals; Arteries; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Coronary Vessels; Disease Models, Animal; Dogs; Electric Stimulation; Female; Male; Microscopy, Electron, Scanning; Platelet Aggregation; Quinazolines; Serotonin | 1986 |
Microscopic measurements of platelet aggregation reveal a low ADP-dependent process distinct from turbidometrically measured aggregation.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Blood Platelets; Dose-Response Relationship, Drug; Edetic Acid; Female; Fibrinolytic Agents; Humans; Kinetics; Male; Nephelometry and Turbidimetry; Platelet Aggregation; Prostaglandins E; Quinazolines | 1983 |
Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers.
Topics: Blood Platelets; Cell Survival; Drug Evaluation; Humans; Male; Platelet Count; Quinazolines | 1984 |
Shortening of platelet survival by induced hypercholesterolaemia in rabbits and its prolongation by anagrelide.
Topics: Animals; Arteriosclerosis; Blood Platelets; Cell Survival; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Diet, Atherogenic; Female; Half-Life; Hypercholesterolemia; Lipoproteins, HDL; Male; Platelet Aggregation; Quinazolines; Rabbits; Thromboxane B2; Triglycerides | 1983 |
Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase.
Topics: Adenine; Adenosine Diphosphate; Collagen; Depression, Chemical; Drug Synergism; Humans; Imidazoles; Oxidoreductases; Phosphodiesterase Inhibitors; Platelet Aggregation; Quinazolines; Thromboxane-A Synthase | 1982 |
Inhibitors of immune complex induced human platelet aggregation and release in plasma.
Topics: Antibodies; Antigen-Antibody Complex; Aspirin; Blood Platelets; Depression, Chemical; Dipyridamole; DNA; Humans; Imidazoles; Indomethacin; Lupus Erythematosus, Systemic; Male; Platelet Aggregation; Quinazolines; Receptors, Fc; Sulfinpyrazone | 1982 |
Disposition of anagrelide, an inhibitor of platelet aggregation.
Topics: Adult; Humans; Imidazoles; Kinetics; Male; Platelet Aggregation; Quinazolines | 1981 |
[Anagrelide. A selective inhibitor of thrombopoiesis].
Topics: Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Quinazolines | 1996 |
Interferon-alpha in the treatment of essential thrombocythemia.
Topics: Bone Marrow; Clinical Trials as Topic; Follow-Up Studies; Humans; Immunologic Factors; Interferon-alpha; Megakaryocytes; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Remission Induction; Thrombocythemia, Essential | 1996 |
The effects of anagrelide on human megakaryocytopoiesis.
Topics: Adult; Blood Platelets; Cell Division; Cell Survival; Cells, Cultured; Cellular Senescence; Female; Humans; Male; Megakaryocytes; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Stem Cells | 1997 |
Anagrelide for essential thrombocythemia.
Topics: Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Edema; Fees, Pharmaceutical; Humans; Hypotension; Platelet Aggregation Inhibitors; Quinazolines; Tachycardia; Thrombocytosis | 1997 |
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
Topics: Female; Humans; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Paraneoplastic Syndromes; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 1998 |
Successful treatment of essential thrombocythemia with anagrelide in a child.
Topics: Child; Female; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 1998 |
Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Thrombocythemia, Essential; Treatment Outcome | 1998 |
[Chronic myeloproliferative diseases].
Topics: Chronic Disease; Female; Fibrinolytic Agents; Humans; Interferons; Leukemia, Myeloid; Male; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 1998 |
Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
Topics: Aged; Antineoplastic Agents; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Platelet Aggregation Inhibitors; Quinazolines; Recurrence; Thrombocythemia, Essential | 1998 |
[Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis; Treatment Outcome | 1998 |
Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers?
Topics: Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Humans; Models, Economic; Platelet Aggregation Inhibitors; Policy Making; Quinazolines; Thrombocythemia, Essential | 1999 |
Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide.
Topics: Bleeding Time; Blood Platelets; Child; Humans; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential | 1999 |
Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia.
Topics: Aged; Blood Platelets; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Prospective Studies; Quinazolines | 1999 |
Anagrelide-induced cardiomyopathy.
Topics: Cardiomyopathies; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines | 2000 |
[Essential thrombocythemia as a cause of headache in young woman].
Topics: Adult; Combined Modality Therapy; Female; Fibrinolytic Agents; Headache; Humans; Plateletpheresis; Quinazolines; Thrombocytosis | 2000 |
Long-term use of anagrelide in young patients with essential thrombocythemia.
Topics: Adolescent; Adult; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Thrombocythemia, Essential; Thrombosis; Treatment Outcome | 2001 |
[Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide].
Topics: Adult; Aged; Female; Fibrinolytic Agents; Humans; Immunoenzyme Techniques; Male; Middle Aged; Platelet Count; Platelet-Derived Growth Factor; Quinazolines; Thrombocythemia, Essential; Thromboxane B2 | 2000 |
Thrombocytosis--report of a case.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis | 2000 |
Hydroxyurea and periodicity in myeloproliferative disease.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Busulfan; Female; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Periodicity; Platelet Count; Polycythemia Vera; Quinazolines | 2001 |
[Anagrelide in primary thrombocythemia].
Topics: Adult; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Retrospective Studies; Thrombocythemia, Essential | 2001 |
[How should patients with essential thrombocythemia be treated?].
Topics: Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxyurea; Leukemia; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2001 |
Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation.
Topics: Acetylcholinesterase; Animals; Antigens, CD34; Biomarkers; Cell Movement; Cells, Cultured; Chemokine CXCL12; Chemokines, CXC; Fetal Blood; Humans; Megakaryocytes; Mice; Mice, Inbred BALB C; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Ploidies; Quinazolines; Thrombocytopenia | 2001 |
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Remission Induction; Thrombocytosis | 2002 |
Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.
Topics: Blood Platelets; Bone Marrow Cells; Cell Differentiation; Cell Division; Cell Survival; Flow Cytometry; Hematopoiesis; Humans; Indium Radioisotopes; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2002 |
Cost-effectiveness considerations in the treatment of essential thrombocythemia.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Quinazolines; Thrombocytosis | 2002 |
Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?
Topics: Animals; Blood Platelets; Cell Differentiation; Cells, Cultured; Dogs; Humans; Megakaryocytes; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins; Quinazolines; Rabbits; Rats; Rats, Wistar; Receptors, Cytokine; Receptors, Thrombopoietin; Species Specificity; Thrombocytopenia; Thrombopoietin; Transfection | 2002 |
[Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2002 |
[Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
Topics: Blood Platelets; Chronic Disease; Fibrinolytic Agents; Humans; Megakaryocytes; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Proliferating Cell Nuclear Antigen; Quinazolines; Reference Values; Retrospective Studies; Thrombocytosis; Thrombopoiesis | 2002 |
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incidence; Middle Aged; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia; Thrombosis | 2003 |
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chronic Disease; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fibrinolytic Agents; Humans; Imatinib Mesylate; Male; Medical Records Systems, Computerized; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinazolines; Retrospective Studies; Survival Analysis | 2003 |
Severe hypersensitivity pneumonitis associated with anagrelide.
Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Drug Interactions; Female; Humans; Hydroxyurea; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 2003 |
Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
Topics: Adult; Aged; Biopsy; Blood Platelets; Bone Marrow; Chronic Disease; Drug Evaluation; Humans; Immunohistochemistry; Middle Aged; Myeloproliferative Disorders; Platelet Count; Quinazolines; Retrospective Studies; Thrombocytosis | 2003 |
Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antithrombin III; Child; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Protein C; Prothrombin; Quinazolines; Reference Values; Thrombocythemia, Essential; Thrombophilia | 2003 |
Essential thrombocythaemia in children: is a treatment needed?
Topics: Adult; Aspirin; Child; Clinical Trials, Phase II as Topic; Humans; Interferon-alpha; Quinazolines; Thrombocythemia, Essential | 2004 |
Thrombocytosis.
Topics: Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 2004 |
Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia.
Topics: Adult; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential | 2004 |
Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia.
Topics: Aged; Female; Hallucinations; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2004 |
Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.
Topics: Adult; Blood Platelets; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Factor 4; Quinazolines; Thrombocythemia, Essential; Vascular Endothelial Growth Factor A | 2004 |
A long-term study of young patients with essential thrombocythemia treated with anagrelide.
Topics: Adult; Anemia; Female; Hemoglobins; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Stomach Diseases; Tachycardia; Thrombocythemia, Essential; Time Factors | 2004 |
Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
Topics: Cardiomyopathies; Female; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential | 2004 |
PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide.
Topics: Blood Platelets; Fibroblast Growth Factor 2; Growth Substances; Humans; Middle Aged; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Quinazolines; RNA, Messenger; Thrombocythemia, Essential; Transforming Growth Factor beta | 2005 |
Renal tubular injury associated with anagrelide use.
Topics: Humans; Kidney Tubules; Male; Middle Aged; Necrosis; Quinazolines | 2005 |
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Safety; Time Factors | 2005 |
Successful outcome with anagrelide in pregnancy.
Topics: Adult; Blood Cell Count; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Splenomegaly; Thrombocytosis | 2005 |
[Anagrelide in the treatment of thrombocythemia essential (ET)].
Topics: Adult; Aged; Blood Platelets; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Poland; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Time Factors; Treatment Outcome | 2004 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis | 2005 |
High-performance liquid chromatography-mass spectrometry method for determination of anagrelide in human plasma.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Fibrinolytic Agents; Humans; Mass Spectrometry; Quinazolines; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Moyamoya syndrome in an adolescent with essential thrombocythemia: successful intracranial carotid stent placement.
Topics: Adolescent; Angiography; Brain; Cerebral Revascularization; Cerebrovascular Circulation; Female; Humans; Moyamoya Disease; Quinazolines; Regional Blood Flow; Stents; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2005 |
Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antigens, CD34; Cell Differentiation; Cell Movement; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 3; Fibrinolytic Agents; Hematopoietic Stem Cells; Humans; Imidazoles; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines | 2005 |
High-output heart failure associated with anagrelide therapy for essential thrombocytosis.
Topics: Adult; Cardiac Output; Heart Failure; Humans; Male; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2005 |
Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Humans; Hydroxyurea; Immunohistochemistry; Megakaryocytes; Myelodysplastic Syndromes; Quinazolines; Retrospective Studies; Thrombopoiesis | 2005 |
Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
Topics: Adult; Aged; Blood Coagulation; Female; Humans; Lipoproteins; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Factor 4; Quinazolines; Thrombocythemia, Essential; Thrombosis | 2005 |
Current treatment of myelofibrosis.
Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Management; Drug Therapy, Combination; Esophageal and Gastric Varices; Farnesyltranstransferase; Gastrointestinal Hemorrhage; Hematopoietic Cell Growth Factors; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quinazolines; Spleen; Splenectomy; Thalidomide; Transplantation, Homologous | 2005 |
New approaches to the treatment of thrombocytosis.
Topics: Humans; Hydroxyurea; Interferon-alpha; Myeloproliferative Disorders; Platelet Count; Quinazolines; Thrombocytosis | 2003 |
A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions.
Topics: Antigens, CD34; Cell Differentiation; Cell Line; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Interleukin-3; Models, Biological; Phosphotyrosine; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Ploidies; Proto-Oncogene Proteins; Quinazolines; Receptors, Cytokine; Receptors, Thrombopoietin; Thrombopoietin | 2006 |
'Double hit' from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide.
Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Drug Hypersensitivity; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia, Pneumococcal; Quinazolines; Thrombocythemia, Essential | 2006 |
Bilateral adrenal hemorrhage associated with essential thrombocytosis.
Topics: Adrenal Insufficiency; Aged; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Quinazolines; Thrombocythemia, Essential | 2006 |
Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Count; Cell Differentiation; Cell Lineage; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Hydroxyurea; Megakaryocytes; Quinazolines | 2006 |
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Chronic Disease; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic; Treatment Outcome | 2006 |
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Topics: Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 2006 |
Effects of anagrelide on megakaryopoiesis and platelet production.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Differentiation; Drug Evaluation; Humans; Hydroxyurea; Megakaryocytes; Mutagenesis; Platelet Aggregation Inhibitors; Ploidies; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombopoiesis; World Health Organization | 2006 |
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 20; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia; Middle Aged; Quinazolines; Remission Induction; Thrombocythemia, Essential; Treatment Outcome | 2006 |
Long-term use of anagrelide in the treatment of children with essential thrombocythemia.
Topics: Adolescent; Child; Female; Humans; Male; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2006 |
Coronary artery intervention after cytostatics treatment in unstable angina patient with essential thrombocythemia. A case report and literature review.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Humans; Hydroxyurea; Male; Middle Aged; Quinazolines; Stents; Thrombocythemia, Essential | 2006 |
[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thrombocytosis | 2006 |
Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.
Topics: Antigens, CD; Benzamides; Bone Marrow Cells; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 3; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Remission Induction; Splenomegaly; Translocation, Genetic | 2007 |
Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis.
Topics: Benzamides; Blood Flow Velocity; Blood Platelets; Hematocrit; Humans; Imatinib Mesylate; Piperazines; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Polycythemia; Pyrimidines; Quinazolines; Thrombocytosis; Time Factors | 2007 |
[Appearance of leg ulcers associated with intake of anagrelide].
Topics: Adult; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Male; Quinazolines; Thrombocytosis | 2007 |
Acute coronary syndromes and Anagrelide.
Topics: Angina Pectoris, Variant; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2007 |
[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
Topics: Adult; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Quinazolines; Thrombocytosis | 2007 |
Chronic myeloid leukemia evolving after idiopathic myelofibrosis.
Topics: Adult; Blood Cell Count; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Megakaryocytes; Primary Myelofibrosis; Quinazolines; Splenomegaly; Thrombocytopenia; Translocation, Genetic | 2007 |
Essential thrombocythaemia treatment options: addressing patient-specific needs.
Topics: Disease Management; Health Services Needs and Demand; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Risk Factors; Thrombocythemia, Essential | 2007 |
Options in the management of essential thrombocythaemia.
Topics: Age Factors; Disease Management; Humans; Hydroxyurea; Interferons; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential | 2007 |
Practical approach to treating essential thrombocythaemia: case studies.
Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; Middle Aged; Pipobroman; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Warfarin | 2007 |
Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2008 |
The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
Topics: Adult; Aged; Blood Platelets; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Female; Hemoglobins; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Quinazolines; Retrospective Studies; Thrombocytosis | 2008 |
Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential | 2008 |
Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Data Collection; Europe; Humans; Janus Kinase 2; Middle Aged; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Quinazolines; Thrombocythemia, Essential; Young Adult | 2009 |
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
Topics: Alleles; Chronic Disease; Female; Humans; Hydroxyurea; Janus Kinase 2; Male; Mutation; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Prospective Studies; Quinazolines | 2009 |
Atypical Takotsubo syndrome during anagrelide therapy.
Topics: Aged; Coronary Angiography; Electrocardiography; Female; Humans; Phosphodiesterase Inhibitors; Quinazolines; Takotsubo Cardiomyopathy | 2009 |
[Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocythemia, Essential | 2009 |
Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
Topics: Aged; Aspirin; Blood Cell Count; Blood Chemical Analysis; Blood Transfusion; Drug Resistance; Erythropoietin; Fatal Outcome; Female; Humans; Hydroxyurea; Jehovah's Witnesses; Kidney Failure, Chronic; Kidney Function Tests; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Recombinant Proteins; Renal Dialysis; Thrombocythemia, Essential | 2009 |
Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Product Surveillance, Postmarketing; Quinazolines; Thrombocythemia, Essential; Thrombosis; Young Adult | 2010 |
Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction.
Topics: Antigens, CD34; Blood Platelets; Cell Line; GATA1 Transcription Factor; Gene Expression Regulation; Humans; Megakaryocytes; Nuclear Proteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines; Receptors, Thrombopoietin; Signal Transduction; Transcription Factors; Transcription, Genetic | 2010 |
[Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 2010 |
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Child; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Withholding Treatment; Young Adult | 2011 |
Anagrelide and cardiovascular events. Much ado about nothing?
Topics: Cardiovascular Diseases; Female; Humans; Male; Quinazolines; Thrombocythemia, Essential; Withholding Treatment | 2011 |
Melanonychia secondary to hydroxyurea.
Topics: Aged; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hyperpigmentation; Nail Diseases; Platelet Aggregation Inhibitors; Plateletpheresis; Quinazolines; Risk Factors | 2012 |
Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine.
Topics: Adult; Appetite Depressants; Female; Humans; Phentermine; Platelet Aggregation Inhibitors; Quinazolines; Takotsubo Cardiomyopathy; Thrombocythemia, Essential | 2012 |
Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Female; Humans; Hydroxyurea; Janus Kinase 2; Male; Megakaryocytes; Middle Aged; Mutation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thrombocythemia, Essential | 2012 |
Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Femoral Vein; Humans; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis | 2012 |
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Interferons; International Agencies; Kaplan-Meier Estimate; Leukocyte Count; Male; Middle Aged; Organ Size; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Remission Induction; Retrospective Studies; Spain; Spleen; Survival Analysis; Thrombocythemia, Essential; Treatment Outcome; Young Adult | 2013 |
The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment.
Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors; Quinazolines; Risk Assessment; Thrombocythemia, Essential | 2013 |
[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with othe
Topics: Adult; Aged; Czech Republic; Female; Fibrinolytic Agents; Humans; Incidence; Male; Middle Aged; Myeloproliferative Disorders; Quinazolines; Registries; Thrombocythemia, Essential; Thrombosis | 2013 |
Acute myocardial infarction and anagrelide.
Topics: Adult; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Quinazolines | 2013 |
Essential thrombocytemia progressing to Ph+ chronic myeloid leukemia with megakaryoblastic blasts, following anagrelide withdrawal.
Topics: Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocyte Progenitor Cells; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2014 |
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Polycythemia Vera; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Thrombosis | 2013 |
Successful management of acute bleeding in essential thrombocythemia using automated cell separator.
Topics: Administration, Oral; Adolescent; Automation; Blood Platelets; Body Weight; Cell Separation; Female; Hemorrhage; Humans; Hydroxyurea; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 2014 |
Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition?
Topics: Aged; Dermatomyositis; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Erythema; Female; Humans; Hydroxyurea; Leg Ulcer; Lichenoid Eruptions; Precancerous Conditions; Primary Myelofibrosis; Quinazolines | 2014 |
Reversible dilated cardiomyopathy associated with long-term anagrelide therapy in a patient with chronic myeloproliferative disease: a serial 2-dimensional speckle tracking echocardiographic study.
Topics: Aged; Cardiomyopathy, Dilated; Drug Administration Schedule; Echocardiography; Humans; Male; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines | 2014 |
Solid-phase synthesis of anagrelide sulfonyl analogues.
Topics: Amino Acids; Combinatorial Chemistry Techniques; Cyclization; Fibrinolytic Agents; Fluorenes; Quinazolines; Solid-Phase Synthesis Techniques; Sulfinic Acids | 2014 |
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Topics: Aged; Alleles; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2015 |
Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
Topics: Adult; Aged; Blood Platelets; Case-Control Studies; Female; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Male; Mean Platelet Volume; Middle Aged; Mutation; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Thrombosis | 2014 |
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo
Topics: Anticoagulants; Disease Susceptibility; Drug Interactions; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Incidence; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Myeloproliferative Disorders; Phlebotomy; Platelet Aggregation Inhibitors; Postoperative Complications; Pregnancy; Pregnancy Complications, Hematologic; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention; Thrombophilia; Venous Thromboembolism; von Willebrand Diseases | 2014 |
Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
Topics: Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Fetal Blood; Hematopoietic Stem Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Megakaryocytes; Microfilament Proteins; Myosins; Phosphodiesterase 3 Inhibitors; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Quinazolines; Signal Transduction; Thrombocythemia, Essential; Thrombopoiesis; Time Factors; Transcription Factors | 2015 |
Essential thrombocythaemia.
Topics: Age Factors; Antineoplastic Agents; Blood Platelets; Calreticulin; Gene Expression; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Janus Kinase 2; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Receptors, Thrombopoietin; Risk Factors; Thrombocythemia, Essential | 2015 |
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual; Female; Follow-Up Studies; Hemorrhage; Hemorrhagic Disorders; Humans; Hydroxyurea; Leukocyte Count; Male; Middle Aged; Phlebotomy; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Thrombophilia; Thrombosis; Young Adult | 2015 |
Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Aspirin; Female; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Male; Mutation, Missense; Philadelphia Chromosome; Platelet Count; Prospective Studies; Quinazolines; Registries; Risk Factors; Thrombocytosis; Thrombosis | 2016 |
The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis.
Topics: Activating Transcription Factor 4; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Computational Biology; Databases, Genetic; Eukaryotic Initiation Factor-2; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networks; Hematologic Agents; Humans; Megakaryocytes; Oligonucleotide Array Sequence Analysis; Phosphorylation; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Quinazolines; Repressor Proteins; Signal Transduction; Thrombopoiesis; Time Factors | 2015 |
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Blood Platelets; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2015 |
Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Calreticulin; Child; Female; Follow-Up Studies; Gene Expression; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential | 2016 |
JAK2+ Essential Thrombocythemia in a Young Girl With Budd-Chiari Syndrome: Diagnostic and Therapeutic Considerations When Adult Disease Strikes the Young.
Topics: Budd-Chiari Syndrome; Child; Female; Humans; Janus Kinase 2; Liver Transplantation; Platelet Aggregation Inhibitors; Quinazolines; Splenectomy; Thrombocythemia, Essential | 2016 |
[Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hungary; Hydroxyurea; Interferons; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Survival Analysis; Thrombocythemia, Essential; Treatment Failure; Treatment Outcome | 2016 |
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.
Topics: Bone Marrow Examination; Delphi Technique; Diagnosis, Differential; Disease Management; DNA Mutational Analysis; Humans; Hydroxyurea; Janus Kinase 2; Mutation, Missense; Platelet Count; Polycythemia Vera; Prognosis; Quinazolines; Receptors, Thrombopoietin; Risk Assessment; Surveys and Questionnaires; Thrombocythemia, Essential; Thrombophilia | 2016 |
Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.
Topics: Aged; Blood Platelets; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukocyte Count; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Quinazolines; Registries; Risk Assessment; Thrombocythemia, Essential; Thrombosis | 2016 |
Anagrelide and Mutational Status in Essential Thrombocythemia.
Topics: Adult; Calreticulin; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential; Treatment Outcome | 2016 |
Inhibition of human primary megakaryocyte differentiation by anagrelide: a gene expression profiling analysis.
Topics: Cell Differentiation; Cells, Cultured; Fetal Blood; Gene Expression Profiling; Humans; Megakaryocyte Progenitor Cells; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines; Transcription Factors | 2016 |
Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Hemorrhage; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Quinazolines; Retrospective Studies; Risk Factors; Turkey; Venous Thromboembolism; Young Adult | 2016 |
A Rare Case of Acute Myeloid Leukemia with a t(2;3) Chromosomal Translocation Characterized by Thrombophilia and Chemoresistance.
Topics: Blood Platelets; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Proto-Oncogenes; Quinazolines; Stem Cell Transplantation; Thrombophilia; Transcription Factors; Translocation, Genetic | 2016 |
[Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide].
Topics: Child; Hematologic Neoplasms; Humans; Platelet Aggregation Inhibitors; Prognosis; Quinazolines; Thrombocythemia, Essential | 2016 |
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report.
Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Pancreatitis; Phosphodiesterase Inhibitors; Quinazolines; Thrombocythemia, Essential | 2016 |
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hungary; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombosis | 2017 |
Anagrelide may induce acute pancreatitis: the evidences are growing.
Topics: Adult; Humans; Male; Pancreatitis; Platelet Aggregation Inhibitors; Quinazolines | 2017 |
[An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients].
Topics: Female; Humans; Hungary; Male; Myeloproliferative Disorders; Philadelphia Chromosome; Platelet Aggregation Inhibitors; Quinazolines; Registries | 2017 |
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.
Topics: Adrenomedullin; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell-Derived Microparticles; Endothelin-1; Endothelium, Vascular; Female; Humans; Hydroxyurea; Male; Middle Aged; Nitric Oxide; Quinazolines; Retrospective Studies; Thrombocythemia, Essential | 2017 |
Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide.
Topics: Aged; Female; Humans; Lung Diseases, Interstitial; Platelet Aggregation Inhibitors; Pneumonia; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2017 |
Hemorrhage and Infarction of the Conjunctiva and Orbit in Essential Thrombocythemia.
Topics: Aged, 80 and over; Biopsy; Conjunctiva; Eye Hemorrhage; Female; Hematologic Agents; Humans; Hydroxyurea; Orbit; Quinazolines; Thrombocythemia, Essential; Thrombosis; Tomography, X-Ray Computed; Treatment Outcome; Visual Acuity | 2017 |
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Male; Middle Aged; Neoplasms, Second Primary; Quinazolines; Thrombocythemia, Essential; Young Adult | 2017 |
Efficacy and safety of anagrelide in childhood essential thrombocythemia.
Topics: Child; Female; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2017 |
Is anagrelide safe during pregnancy?
Topics: Abortion, Spontaneous; Adult; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Uterine Hemorrhage | 2017 |
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk | 2017 |
Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia.
Topics: Age Factors; Aged; Electrocardiography; Female; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Tachycardia, Ventricular; Thrombocythemia, Essential | 2018 |
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report.
Topics: Adolescent; Amputation, Traumatic; Finger Injuries; Fingers; Humans; Hydroxyurea; Male; Platelet Count; Quinazolines; Replantation; Splenectomy; Splenic Rupture; Thrombocytosis | 2018 |
Anagrelide and the CALR mutation allele burden in essential thrombocythemia.
Topics: Aged; Alleles; Calreticulin; Humans; Male; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential | 2018 |
Synthesis and characterization of metals-substituted cobalt ferrite [M
Topics: Anti-Infective Agents; Candida albicans; Cobalt; Enterococcus faecalis; Ferric Compounds; Klebsiella pneumoniae; Nanoparticles; Quinazolines | 2018 |
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow; Disease Progression; Disease-Free Survival; Drug Approval; Female; Fibrosis; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Thrombocythemia, Essential; Thrombosis; Treatment Outcome; Young Adult | 2019 |
Anagrelide is an anti-megakaryocytic and not an anti-platelet agent.
Topics: Blood Platelets; Humans; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines | 2019 |
Anagrelide for Gastrointestinal Stromal Tumor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclic Nucleotide Phosphodiesterases, Type 3; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Stromal Tumors; High-Throughput Screening Assays; Humans; Mice; Platelet Aggregation Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Acute ischemic stroke in the setting of essential thrombocytemia (clinical cases).
Topics: Brain Ischemia; Cerebrovascular Circulation; Female; Gene Frequency; Humans; Janus Kinase 2; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Stroke; Thrombocythemia, Essential; Treatment Outcome | 2018 |
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential; Treatment Outcome; Young Adult | 2019 |
Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydroxyurea; Japan; Quinazolines; Retrospective Studies; Thrombocythemia, Essential | 2019 |
Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells.
Topics: Cell Cycle; Cell Differentiation; Humans; Induced Pluripotent Stem Cells; Megakaryocyte Progenitor Cells; Megakaryocytes; Quinazolines | 2020 |
Anagrelide with low-dose aspirin promptly epithelized ulceronecrotic lesion secondary to essential thrombocythemia.
Topics: Aspirin; Bone Marrow; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Janus Kinase 2; Karyotyping; Male; Middle Aged; Mutation; Necrosis; Quinazolines; Re-Epithelialization; Skin; Skin Ulcer; Thrombocythemia, Essential; Toes; Treatment Outcome | 2020 |
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day.
Topics: Adult; Aged; Aged, 80 and over; Cytoreduction Surgical Procedures; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Safety; Thrombocythemia, Essential; Treatment Outcome; Young Adult | 2020 |
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Disease Management; Disease Susceptibility; Drug Substitution; Female; Follow-Up Studies; Health Care Surveys; Humans; Italy; Male; Middle Aged; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Thrombocythemia, Essential; Thrombosis; Treatment Outcome; Young Adult | 2020 |
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
Topics: Aspirin; Drug Therapy, Combination; Health Care Surveys; Humans; Hungary; Hydroxyurea; Quinazolines; Registries; Thrombocythemia, Essential; Thrombosis; Treatment Outcome | 2020 |
Acute Myocardial Infarction in an Adolescent Receiving Anagrelide for Essential Thrombocythemia with Underlying Persistent Coronary Endothelial Dysfunction.
Topics: Acetylcholine; Adolescent; Coronary Angiography; Coronary Vessels; Echocardiography; Endothelium, Vascular; Fibrinolytic Agents; Fibrosis; Heart Function Tests; Humans; Janus Kinase 2; Magnetic Resonance Imaging; Male; Nitroglycerin; Percutaneous Coronary Intervention; Quinazolines; Radionuclide Imaging; ST Elevation Myocardial Infarction; Thrombectomy; Thrombocythemia, Essential; Tomography, Optical Coherence; Tunica Intima; Vasodilator Agents | 2020 |
Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
Topics: Aged; Calreticulin; Creatinine; Disease Progression; Female; Humans; Hydroxyurea; Janus Kinase 2; Kidney Diseases; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Treatment Outcome | 2021 |
Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms.
Topics: Humans; Hydroxyurea; Kidney Function Tests; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2021 |
Leg Ulcers Associated with Anagrelide
Topics: Humans; Leg Ulcer; Quinazolines | 2021 |
Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Cryoelectron Microscopy; Cyclic Nucleotide Phosphodiesterases, Type 3; Drug Design; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Intracellular Signaling Peptides and Proteins; Mice; Multiprotein Complexes; Naphthyridines; Pyridazines; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
A toe ulcer in a patient with essential thrombocythemia successfully treated with a combination of anagrelide and prednisolone.
Topics: Humans; Prednisolone; Quinazolines; Thrombocythemia, Essential; Toes; Ulcer | 2022 |
Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose.
Topics: Cytoreduction Surgical Procedures; Headache; Humans; Japan; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Quinazolines | 2022 |
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.
Topics: Cytoreduction Surgical Procedures; Humans; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential; Thrombocytosis; Thrombosis | 2022 |
Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia.
Topics: Hemorrhage; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombosis | 2022 |
Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population.
Topics: Child; Erythropoietin; Humans; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 2022 |
Identification and enrichment of a UV-induced degradant of Anagrelide drug substance.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Mass Spectrometry; Quinazolines | 2023 |